In conclusion, MSI2 and RBM17 played a radioresistant role in lung cancer radiotherapy, and RBM17 played a more important role for MSI2 in lung cancer radioresistance, which is consistent with the mechanism that MSI2 promotes radioresistance by activating ATR through the assistance of RBM17 into the nucleus. Here, MSI2 is linked to lung carcinoma.